Home/Pipeline/RG6139 (RO7247669)

RG6139 (RO7247669)

Hepatocellular Carcinoma

Phase IIIActiveNCT05098405

Key Facts

Indication
Hepatocellular Carcinoma
Phase
Phase III
Status
Active
Company

About Chugai Pharmaceutical

Chugai Pharmaceutical's mission is to create innovative, best-in-class therapeutics that contribute to human health worldwide, with a strategic focus on oncology and niche specialty areas. Its defining achievement is the construction of a highly successful, decades-long strategic alliance with Roche, which provides a unique two-way pipeline flow, global scale, and financial stability. The company's strategy centers on maintaining a powerful independent R&D engine to generate proprietary assets while simultaneously co-developing and commercializing Roche's global portfolio in its key markets. This model has established Chugai as Japan's premier biopharmaceutical innovator and a vital node in Roche's global network.

View full company profile

Other Hepatocellular Carcinoma Drugs

DrugCompanyPhase
Namodenoson (CF102)Can Fite BiopharmaPhase IIb/III
DCR-MYCDicerna PharmaceuticalsPreclinical
RYZ801RayzeBioPreclinical
ALN-BCATAlnylam PharmaceuticalsPhase 1
HCC ProgramArcellxDiscovery
TTFieldsNovocurePilot
RP2ReplimunePhase 2
188RNL-BAMPlus TherapeuticsPreclinical
TemferonGenenta SciencePreclinical